Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-1

Els were negative correlated with the levels of RhoA protein in HCC with adjusted -0.447 and two-tailed probability, n = 53, = 0.01.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-3

S of DLC2 protein than PCLT. = 0.02.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-2

H expression confirmed by Western blotting was used as positive controls (), whereas negative controls were done by omitting the primary antibody (). The representative positive expression of DLC2 () and negative expression of DLC2 () in HCC specimens were presented. Kaplan-Meier survival curves for DLC2-positive expression group (n = 33) and DLC2-negative expression group (n = 95) based on results of immunohistochemistry (). HCC patients with DLC2-negative expression revealed significant poor prognosis than those with DLC2-positive expression, Log-rank test, = 0.003.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-0

S of DLC2 protein than PCLT. = 0.02.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Receptor-ligand binding affinities and maximum numbers of binding sites for ITF on epithelial and epidermal cells(n = 6).

**<p><i>P</i><0.01 compared with HaCaT cells; <b><i>^##</i></b><i>P</i><0.01 compared with HT-29 cells;</p

Association of ITF with epithelial cells.

<p>Association of ITF with epithelial cells.</p

Analyses of binding of ITF to intestinal epithelial cells and to epidermal cells.

<p>Analyses of binding of ITF to intestinal epithelial cells and to epidermal cells.</p

Competition experiment with unlabeled ligand with epithelial cells.

<p>Competition experiment with unlabeled ligand with epithelial cells.</p

Association between CYP1A2 and CYP1B1 Polymorphisms and Colorectal Cancer Risk: A Meta-Analysis

<div><p>Background</p><p>The previous published data on the association between CYP1A2*F (rs762551), CYP1B1 Leu432Val (rs1056836), Asn453Ser (rs180040), and Arg48Gly (rs10012) polymorphisms and colorectal cancer risk remained controversial.</p><p>Methodology/Principal Findings</p><p>The purpose of this study is to evaluate the role of CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly genotypes in colorectal cancer susceptibility. We performed a meta-analysis on all the eligible studies that provided 5,817 cases and 6,544 controls for CYP1A2*F (from 13 studies), 9219 cases and 10406 controls for CYP1B1 Leu432Val (from 12 studies), 6840 cases and 7761 controls for CYP1B1 Asn453Ser (from 8 studies), and 4302 cases and 4791 controls for CYP1B1Arg48Gly (from 6 studies). Overall, no significant association was found between CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly and colorectal cancer risk when all the eligible studies were pooled into the meta-analysis. And in the subgroup by ethnicity and source of controls, no evidence of significant association was observed in any subgroup analysis.</p><p>Conclusions/Significance</p><p>In summary, this meta-analysis indicates that CYP1A2*F, CYP1B1 Leu432Val, Asn453Ser, and Arg48Gly polymorphisms do not support an association with colorectal cancer, and further studies are needed to investigate the association. In addition, our work also points out the importance of new studies for CYP1A2*F polymorphism in Asians, because high heterogeneity was found (dominant model: <i>I</i>² = 81.3%; heterozygote model: <i>I</i>² = 79.0).</p></div

Dissociation of ITF from epithelial cells.

<p>Dissociation of ITF from epithelial cells.</p